Arrowhead Pharmaceuticals strengthens plozasiran’s severe hypertriglyceridemia case with durable ACC.26 data
Arrowhead Pharmaceuticals’ plozasiran posted durable triglyceride reductions at ACC.26. Read what the long-term data could change next.
Pharma & Biotech
Medical Devices & Diagnostics
CorVista Health expands machine-learning diagnostics to INOCA with new ACC.26 poster data
CorVista Health presents machine-learned non-invasive INOCA detection data at ACC.26. Analysis of what this means for cardiology and women's heart care. Read more.